Drug intelligence / Profile preview

Concevit F

Development stage: Unknown
Lead developer: Sugen Pharma
Modality: Small Molecules
Administration: Oral

Overview

Concevit F is a branded generic nutraceutical combination developed and marketed by Sugen Pharma, a pharmaceutical company based in Ahmedabad, India. The product is specifically formulated for the management of Polycystic Ovary Syndrome (PCOS), ovulatory dysfunction, and female infertility. It typically contains a synergistic blend of myo-inositol, d-chiro-inositol, levomefolic acid (L-methylfolate), and cholecalciferol (Vitamin D3). These components work together to improve insulin sensitivity, restore hormonal balance, and enhance oocyte quality by addressing the underlying metabolic and endocrine imbalances associated with PCOS and related reproductive disorders.

Brand names: Concevit F
Other names: Concevit-F

Targets

INSR (Insulin receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Concevit F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concevit F.

Explore the full profile